KDM1A and acute myeloid leukemia: ORY-1001 is another potent and selective LSD1 inhibitor that increases H3K4me2 levels in target genes, promotes blast differentiation, and diminishes leukemic stem cell capacity in acute myeloid leukemia (AML).